Mayur Narkhede

935 total citations
40 papers, 320 citations indexed

About

Mayur Narkhede is a scholar working on Oncology, Pathology and Forensic Medicine and Genetics. According to data from OpenAlex, Mayur Narkhede has authored 40 papers receiving a total of 320 indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Oncology, 20 papers in Pathology and Forensic Medicine and 13 papers in Genetics. Recurrent topics in Mayur Narkhede's work include Lymphoma Diagnosis and Treatment (20 papers), CAR-T cell therapy research (11 papers) and Chronic Lymphocytic Leukemia Research (10 papers). Mayur Narkhede is often cited by papers focused on Lymphoma Diagnosis and Treatment (20 papers), CAR-T cell therapy research (11 papers) and Chronic Lymphocytic Leukemia Research (10 papers). Mayur Narkhede collaborates with scholars based in United States, France and Serbia. Mayur Narkhede's co-authors include Chaitra S. Ujjani, Shagun Arora, Aaron T. Gerds, Bhumika J. Patel, Tomas Radivoyevitch, B Przychodzen, M Kalaycio, Jaroslaw P. Maciejewski, Anjali S. Advani and Hetty E. Carraway and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Mayur Narkhede

37 papers receiving 317 citations

Peers

Mayur Narkhede

HEMAT

ONCOL

PFM

GENET

Francesco Autore Italy

Liya Ma China

Mariana Bastos‐Oreiro Spain

Peter Forsyth United Kingdom

Cristina Picone Italy

Cristina Campidelli Italy

Gradimir Janković Serbia

Jeremy Ramdial United States

Zhihong Hu United States

Françoise Delacrétaz Switzerland

Francesco Autore Italy

Mayur Narkhede

94 ×0.7

HEMAT

79 ×0.6

ONCOL

113 ×0.9

PFM

169 ×1.5

GENET

49 ×0.8

Citations per year, relative to Mayur Narkhede Mayur Narkhede (= 1×) peers Francesco Autore

Countries citing papers authored by Mayur Narkhede

Since Specialization

Citations

This map shows the geographic impact of Mayur Narkhede's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mayur Narkhede with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mayur Narkhede more than expected).

Fields of papers citing papers by Mayur Narkhede

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mayur Narkhede. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mayur Narkhede. The network helps show where Mayur Narkhede may publish in the future.

Co-authorship network of co-authors of Mayur Narkhede

This figure shows the co-authorship network connecting the top 25 collaborators of Mayur Narkhede. A scholar is included among the top collaborators of Mayur Narkhede based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mayur Narkhede. Mayur Narkhede is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Narkhede, Mayur & Chaitra S. Ujjani. (2025). Immune Dysfunction and Consequences in Chronic Lymphocytic Leukemia. Journal of the National Comprehensive Cancer Network. 23(3). 1 indexed citations

Shea, Lauren, et al.. (2025). Overall and Cause‐Specific Mortality Among Patients With Cutaneous T‐Cell Lymphoma in the United States. eJHaem. 6(2). e1099–e1099.

Zinzani, Pier Luigi, Anna Maria Frustaci, Mayur Narkhede, et al.. (2025). 436 | UPDATED EFFICACY/SAFETY OF BRUTON TYROSINE KINASE DEGRADER BGB‐16673 IN PATIENTS WITH RELAPSED/REFRACTORY INDOLENT NHL: ONGOING PHASE 1 CaDAnCe‐101 RESULTS. Hematological Oncology. 43(S3). 1 indexed citations

Narkhede, Mayur, Sarah Tomassetti, Madiha Iqbal, et al.. (2024). Tumor-informed ctDNA assessment as a valuable prognostic and predictive biomarker in diffuse large B-cell lymphoma. Frontiers in Oncology. 14. 1407003–1407003. 2 indexed citations

Narkhede, Mayur, Antonio Di Stasi, Lauren Shea, et al.. (2024). Phase 2 Trial of Siltuximab for the Treatment of Cytokine Release Syndrome and Immune Effector Cell Associated Neurotoxicity Related to CAR-T Cell Therapy. Blood. 144(Supplement 1). 3449–3449. 2 indexed citations

Narkhede, Mayur, Nancy L. Bartlett, Sami Ibrahimi, et al.. (2023). A phase 1 first‐in‐human study of GS‐0189, an anti‐signal regulatory protein alpha (SIRPα) monoclonal antibody, in patients with relapsed/refractory (R/R) non‐Hodgkin lymphoma (NHL). SHILAP Revista de lepidopterología. 4(2). 370–380. 6 indexed citations

Winter, Allison, et al.. (2023). Real-World Patient Characteristics, Treatment Patterns, and Outcomes for Patients With Stage III or IV Classic Hodgkin Lymphoma Treated With Frontline ABVD: A Retrospective Database Review in the United States. Clinical Lymphoma Myeloma & Leukemia. 23(7). 527–534. 5 indexed citations

Bair, Steven M., Mayur Narkhede, Elise A. Chong, et al.. (2023). Treatment Intensity and Outcomes in Elderly Patients with DLBCL Receiving First Line Therapy. Blood. 142(Supplement 1). 68–68.

Shea, Lauren, et al.. (2022). Patterns of Utilization and Outcomes of Autologous Stem Cell Transplantation and Chimeric Antigen Receptor T-Cell Therapy in Relapsed or Refractory Diffuse Large B-cell Lymphomas with MYC and BCL2 and/or BCL6 Rearrangements. Clinical Lymphoma Myeloma & Leukemia. 22(11). 825–834.

10.

Winter, Allison, et al.. (2022). Real-World Patient Characteristics, Treatment Patterns, and Outcomes in Patients with Stage III/IV Classic Hodgkin Lymphoma Treated with Frontline ABVD: A Retrospective Analysis Using a Real-World Database. Blood. 140(Supplement 1). 8054–8055. 1 indexed citations

11.

Narkhede, Mayur, Amitkumar Mehta, Stephen M. Ansell, & Gaurav Goyal. (2021). CAR T-cell therapy in mature lymphoid malignancies: clinical opportunities and challenges. Annals of Translational Medicine. 9(12). 1036–1036. 10 indexed citations

12.

Narkhede, Mayur, Maryam Sarraf Yazdy, & Bruce D. Cheson. (2019). Targeting Biology in Non-Hodgkin Lymphoma. Hematology/Oncology Clinics of North America. 33(4). 727–738. 4 indexed citations

13.

Narkhede, Mayur, Shagun Arora, & Chaitra S. Ujjani. (2018). Primary effusion lymphoma: current perspectives. OncoTargets and Therapy. Volume 11. 3747–3754. 52 indexed citations

14.

Narkhede, Mayur & Bruce D. Cheson. (2018). Surrogate Endpoints and Risk Adaptive Strategies in Previously Untreated Follicular Lymphoma. Clinical Lymphoma Myeloma & Leukemia. 18(7). 447–451. 1 indexed citations

15.

Narkhede, Mayur, et al.. (2018). Lack of Prognostic Significance of Pre-Treatment Total Metabolic Tumor Volume (TMTV) in Diffuse Large B-Cell Lymphoma (DLBCL). Blood. 132(Supplement 1). 1720–1720. 1 indexed citations

16.

Sidana, Surbhi, Mayur Narkhede, Paul Elson, et al.. (2017). Neuropathy and efficacy of once weekly subcutaneous bortezomib in multiple myeloma and light chain (AL) amyloidosis. PLoS ONE. 12(3). e0172996–e0172996. 18 indexed citations

17.

Nazha, Aziz, Mayur Narkhede, Tomas Radivoyevitch, et al.. (2016). Incorporation of molecular data into the Revised International Prognostic Scoring System in treated patients with myelodysplastic syndromes. Leukemia. 30(11). 2214–2220. 114 indexed citations

18.

Nazha, Aziz, Mayur Narkhede, Tomas Radivoyevitch, et al.. (2015). The Revised International Prognostic Scoring System "Molecular" (IPSS-Rm), a Validated and Dynamic Model in Treated Patients with Myelodysplastic Syndromes (MDS). Blood. 126(23). 607–607. 2 indexed citations

19.

Nazha, Aziz, Bartlomiej Przychodzen, Hideki Makishima, et al.. (2015). APC mutations in myeloid malignancies: Incidence and impact on leukemogenesis.. Journal of Clinical Oncology. 33(15_suppl). 11047–11047. 1 indexed citations

20.

Narkhede, Mayur, Jason Valent, Chad Cummings, et al.. (2014). Results of an Upfront Myeloma Carepath Pilot with Response-Adapted Therapy. Blood. 124(21). 2620–2620. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact